Hybio Pharmaceutical Co., Ltd. (SHE:300199)
China · Delayed Price · Currency is CNY 21.86
-0.45 (-2.02%)
Oct 30, 2026, 3:04 PM CST
Hybio Pharmaceutical Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Operating Revenue | 1,487 | 927.73 | 547.2 | 383.13 | 692.29 | 730.93 |
Other Revenue | 38.63 | 38.63 | 43 | 48.25 | 12.03 | 5.04 |
| 1,526 | 966.35 | 590.2 | 431.38 | 704.32 | 735.97 | |
Revenue Growth | 69.87% | 63.73% | 36.81% | -38.75% | -4.30% | 1.97% |
Cost of Revenue | 590.06 | 427.23 | 281.47 | 260.42 | 194.83 | 271.88 |
Gross Profit | 935.54 | 539.12 | 308.73 | 170.97 | 509.49 | 464.1 |
Selling, General & Admin | 201.54 | 226.55 | 240.13 | 367.6 | 484.36 | 545.43 |
Research & Development | 212 | 125.19 | 87.33 | 159.6 | 154.79 | 101.94 |
Other Operating Expenses | 24.43 | 11.95 | 8.13 | 12.22 | 16.52 | 16.78 |
Operating Expenses | 453.6 | 370.78 | 341.14 | 542.38 | 691.62 | 734.37 |
Operating Income | 481.94 | 168.34 | -32.41 | -371.41 | -182.13 | -270.27 |
Interest Expense | -85.75 | -98.04 | -106.5 | -120.46 | -103.25 | -87.92 |
Interest & Investment Income | 48.29 | 1.91 | 1.9 | 0.22 | 0.57 | 391.46 |
Currency Exchange Gain (Loss) | 0.84 | 0.84 | 3.64 | 0.29 | 1.64 | -1.55 |
Other Non Operating Income (Expenses) | -16.78 | -16.6 | -10.45 | -11.2 | -10.01 | -16.22 |
EBT Excluding Unusual Items | 428.54 | 56.46 | -143.82 | -502.57 | -293.18 | 15.48 |
Gain (Loss) on Sale of Investments | -0.13 | 0.15 | - | 34.71 | -89.77 | -16.47 |
Gain (Loss) on Sale of Assets | 1.65 | 0.64 | 42.78 | -0.51 | 3.41 | 35.2 |
Asset Writedown | -13.09 | -12.47 | -82.43 | -90.81 | -17.51 | -41.99 |
Legal Settlements | - | - | - | - | - | -1.24 |
Other Unusual Items | 20.91 | 19.45 | 21.06 | 48.08 | 24.24 | 42.71 |
Pretax Income | 437.87 | 64.23 | -162.41 | -511.1 | -372.81 | 33.68 |
Income Tax Expense | 38.42 | 30.2 | 17.68 | 4.34 | -0.27 | 5.24 |
Earnings From Continuing Operations | 399.45 | 34.03 | -180.09 | -515.44 | -372.55 | 28.44 |
Minority Interest in Earnings | 2.41 | 2.54 | 6.44 | 1.57 | 2 | 2.37 |
Net Income | 401.86 | 36.57 | -173.65 | -513.88 | -370.55 | 30.81 |
Net Income to Common | 401.86 | 36.57 | -173.65 | -513.88 | -370.55 | 30.81 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 914 | 914 | 868 | 886 | 882 | 1,027 |
Shares Outstanding (Diluted) | 914 | 914 | 868 | 886 | 882 | 1,027 |
Shares Change | 3.29% | 5.29% | -2.00% | 0.42% | -14.09% | 11.21% |
EPS (Basic) | 0.44 | 0.04 | -0.20 | -0.58 | -0.42 | 0.03 |
EPS (Diluted) | 0.44 | 0.04 | -0.20 | -0.58 | -0.42 | 0.03 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Free Cash Flow | 14.76 | -0.45 | 48.87 | -85.3 | -174.04 | -42.17 |
Free Cash Flow Per Share | 0.02 | - | 0.06 | -0.10 | -0.20 | -0.04 |
Gross Margin | 61.32% | 55.79% | 52.31% | 39.63% | 72.34% | 63.06% |
Operating Margin | 31.59% | 17.42% | -5.49% | -86.10% | -25.86% | -36.72% |
Profit Margin | 26.34% | 3.78% | -29.42% | -119.12% | -52.61% | 4.19% |
Free Cash Flow Margin | 0.97% | -0.05% | 8.28% | -19.77% | -24.71% | -5.73% |
EBITDA | 599.48 | 298.7 | 115.03 | -222.64 | -52.6 | -144.93 |
EBITDA Margin | 39.30% | 30.91% | 19.49% | -51.61% | -7.47% | -19.69% |
D&A For EBITDA | 117.54 | 130.36 | 147.44 | 148.77 | 129.53 | 125.35 |
EBIT | 481.94 | 168.34 | -32.41 | -371.41 | -182.13 | -270.27 |
EBIT Margin | 31.59% | 17.42% | -5.49% | -86.10% | -25.86% | -36.72% |
Effective Tax Rate | 8.77% | 47.02% | - | - | - | 15.57% |
Revenue as Reported | 1,526 | 966.35 | 590.2 | 431.38 | 704.32 | 735.97 |